Reading Time: < 1 minute

Introduction

Erectile dysfunction (ED) affects approximately 30 million American men, with vasculogenic etiologies accounting for up to 80% of cases in those over 40 years. Predominantly linked to atherosclerosis, diabetes, and hypertension—prevalent comorbidities in the U.S. population—arteriogenic insufficiency and veno-occlusive dysfunction impair penile blood flow, compromising erectile rigidity and duration. While phosphodiesterase-5 inhibitors (PDE5i) like sildenafil dominate first-line therapy, refractory cases necessitate surgical intervention. Vascular surgery, particularly penile arterial revascularization and venous ligation, offers a curative potential for younger men with focal arterial occlusions. This longitudinal study evaluates surgical outcomes and sexual function recovery in 450 American males over 10 years, highlighting procedural advancements and patient selection criteria.

Study Methodology

Conducted from 2012–2022 at five tertiary U.S. centers (Mayo Clinic, Johns Hopkins, UCLA, Cleveland Clinic, and Mount Sinai), this prospective cohort enrolled men aged 25–65 with confirmed vasculogenic ED via duplex Doppler ultrasonography (peak systolic velocity <30 cm/s) and pelvic angiography. Exclusion criteria included neurogenic ED, Peyronie's disease, or prior pelvic radiation. Participants underwent microsurgical penile revascularization (inferior epigastric artery to dorsal penile artery anastomosis, n=320) or crural vein ligation for veno-occlusive ED (n=130). Pre- and postoperative assessments utilized the International Index of Erectile Function (IIEF-6) questionnaire, Erection Hardness Score (EHS), and validated sexual encounter profile (SEP) questions. Follow-up intervals were 6 months, 2 years, 5 years, and 10 years, with 92% retention (n=414). Statistical analysis employed Kaplan-Meier survival curves for ED recurrence and mixed-effects models for IIEF trajectories, adjusting for age, BMI, HbA1c, and smoking status (p<0.05 significance). Key Surgical Techniques and Patient Demographics

The cohort was predominantly Caucasian (68%), with 22% African American and 10% Hispanic participants, reflecting U.S. demographics. Mean age was 48.3 years (SD 9.2), baseline IIEF-6 score 8.4 (SD 3.1), and 76% reported PDE5i non-response. Revascularization targeted pudendal artery stenoses (<70% occlusion on angiography), achieving 95% intraoperative patency via microscope-assisted end-to-end anastomosis. Venous procedures ligated incompetent crural veins identified by dynamic infusion cavernosometry. Perioperative complications were low (4.2% hematoma, 1.1% infection), with no mortalities. Clinical Outcomes and Functional Recovery

At 6 months, 78% achieved IIEF-6 scores ?26 (normal erectile function), rising to 82% at 2 years. EHS ?3 (sufficient for penetration) was reported by 85% initially, sustained in 71% at 5 years. SEP2/SEP3 success rates (successful penetration/maintenance) reached 79%/76% at 1 year, plateauing at 68%/65% by 10 years. Kaplan-Meier analysis showed ED-free survival of 72% at 5 years and 59% at 10 years for revascularization versus 64% and 51% for venous ligation (log-rank p=0.12). Predictors of durable success included age <50 (HR 0.62, 95% CI 0.45–0.86), non-diabetic status (HR 0.71, CI 0.52–0.97), and BMI <30 (HR 0.55, CI 0.39–0.78). Graft occlusion, confirmed by repeat angiography in 18%, correlated with progression of systemic atherosclerosis. Comparative Efficacy and Complications

Compared to penile implants (success >90% but irreversible), vascular surgery preserved natural erections in 67% of responders at 10 years, with spontaneous intercourse unassisted by aids in 54%. Partner satisfaction (PEDISPEI scale) improved significantly (p<0.001). Long-term complications included distal embolization (2.3%) and penile hypoesthesia (5.1%), resolving in 80% within 2 years. No increased cardiovascular events versus medical cohorts (HR 1.04, CI 0.88–1.23), underscoring safety in optimized-risk patients. Implications for U.S. Clinical Practice

This study affirms vascular surgery's role in select American males with isolated vasculogenic ED, particularly younger, non-obese non-smokers. Amid rising ED incidence (projected 322 million globally by 2025, per MSH-IFSTART), U.S. guidelines (AUA/ISSMM) should prioritize early angiography in PDE5i failures. Limitations include single-arm design and selection bias toward surgical candidates; randomized trials versus emerging stem cell therapies are warranted. Cost-effectiveness analysis revealed $28,000/QALY gained, competitive with implants.

Conclusion

Penile vascular surgery yields robust, durable improvements in sexual function for American men with arteriogenic ED, with 10-year patency supporting its resurgence. Tailored patient selection maximizes outcomes, offering a bridge between pharmacotherapy and prosthetics in this high-burden condition.

(Word count: 672)